Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Rifkin

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Clinical Lymphoma & Myeloma|June 29, 2007
Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myelomaChristopher A Porter, Robert M Rifkin
Journal of Oncology Practice|September 13, 2017
Biosimilars: Implications for Clinical PracticeRobert M Rifkin, Susan R Peck
Orthopedics|May 21, 2003
Percutaneous treatment of long bone nonunions: the use of autologous bone marrow and allograft bone matrixRoss M Wilkins, Brian T Chimenti, Robert M Rifkin
Future Oncology (London, England)|January 24, 2022
Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case studyJeff P Sharman, Carol F Kirchhoff, Robert M Rifkin
The Lancet. Oncology|November 8, 2016
Safety and efficacy of biosimilars in oncologyHuub Schellekens, Josef S Smolen, Mario Dicato, et al.
Cancer|January 13, 2006
Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trialRobert M Rifkin, Stephanie A Gregory, Ann Mohrbacher, et al.
Future Oncology (London, England)|December 1, 2018
Demystifying biosimilars: development, regulation and clinical useHope S Rugo, Robert M Rifkin, Paul Declerck, et al.
Supportive Cancer Therapy|July 17, 2008
A randomized, multicenter, open-label comparison of the antiemetic efficacy of dolasetron versus ondansetron for the prevention of nausea and vomiting during high-dose myeloablative chemotherapyRomeo A Mandanas, Roy Beveridge, Robert M Rifkin, et al.
British Journal of Haematology|May 15, 2004
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myelomaMohamad A Hussein, Mansoor Saleh, Farhad Ravandi, et al.
Drugs|May 23, 2018
Authors' Reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes"Hillel P Cohen, Andrew Blauvelt, Robert M Rifkin, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Clinical Lymphoma & Myeloma|June 29, 2007
Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myelomaChristopher A Porter, Robert M Rifkin
Journal of Oncology Practice|September 13, 2017
Biosimilars: Implications for Clinical PracticeRobert M Rifkin, Susan R Peck
Orthopedics|May 21, 2003
Percutaneous treatment of long bone nonunions: the use of autologous bone marrow and allograft bone matrixRoss M Wilkins, Brian T Chimenti, Robert M Rifkin
Future Oncology (London, England)|January 24, 2022
Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case studyJeff P Sharman, Carol F Kirchhoff, Robert M Rifkin
The Lancet. Oncology|November 8, 2016
Safety and efficacy of biosimilars in oncologyHuub Schellekens, Josef S Smolen, Mario Dicato, et al.
Cancer|January 13, 2006
Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trialRobert M Rifkin, Stephanie A Gregory, Ann Mohrbacher, et al.
Future Oncology (London, England)|December 1, 2018
Demystifying biosimilars: development, regulation and clinical useHope S Rugo, Robert M Rifkin, Paul Declerck, et al.
Supportive Cancer Therapy|July 17, 2008
A randomized, multicenter, open-label comparison of the antiemetic efficacy of dolasetron versus ondansetron for the prevention of nausea and vomiting during high-dose myeloablative chemotherapyRomeo A Mandanas, Roy Beveridge, Robert M Rifkin, et al.
British Journal of Haematology|May 15, 2004
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myelomaMohamad A Hussein, Mansoor Saleh, Farhad Ravandi, et al.
Drugs|May 23, 2018
Authors' Reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes"Hillel P Cohen, Andrew Blauvelt, Robert M Rifkin, et al.
Pageof 6